Test Price
450 AEDโ Home Collection Available
TFE3 Immunohistochemistry (IHC) Test in UAE | 450 AED | DHA Licensed
Executive Summary & Core Metrics
Diagnostic Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). Tissue validated by dual-pathologist review protocol.
Secure Medical Courier Retrieval
Secure Medical Courier Solid Tissue Specimen Retrieval from referring hospital pathology departments. Temperature-controlled cold-chain transport for FFPE blocks and slides.
Post-Test Clinical Guidance
Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed clinical team. Direct specialist referral coordination available.
Insurance & Billing
Direct Billing Verification via WhatsApp at +971 54 548 8731. Covered by major UAE insurers โ confirm eligibility in under 5 minutes.
Executive Summary
The TFE3 Immunohistochemistry (IHC) test is a critical diagnostic assay for detecting Xp11.2 translocation renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS) through nuclear protein expression analysis in FFPE tumor tissue. This advanced test is performed at our DHA-licensed laboratory (Facility License No. 1143) under ISO 9001:2015 accreditation, with full compliance to UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. The test utilizes validated monoclonal antibodies with heat-induced epitope retrieval and polymer-based detection systems. Price: 450 AED. Turnaround Time: 5 to 7 business days depending on specimen complexity.
Test Overview & Methodology
The TFE3 Immunohistochemistry Test detects nuclear expression of the TFE3 transcription factor protein in formalin-fixed paraffin-embedded (FFPE) tumor tissue, serving as a critical diagnostic and differential marker for Xp11.2 translocation renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS). This assay utilizes validated monoclonal antibodies with heat-induced epitope retrieval and polymer-based detection systems to ensure reproducible, high-specificity nuclear staining interpretation by dual-board-certified surgical pathologists.
| Parameter | TFE3 IHC (Our Test) | TFE3 Break-Apart FISH |
|---|---|---|
| Methodology | Immunohistochemistry (IHC) โ protein-level detection | Fluorescence In-Situ Hybridization โ DNA-level translocation |
| Diagnostic Sensitivity | 97-99% for Xp11.2 RCC | ~99% for TFE3 gene rearrangement |
| Turnaround Time | 5โ7 Days | 10โ14 Days |
| Cost Efficiency | 450 AED โ high value | 1,200โ2,500 AED |
| Clinical Utility | First-line screening; rapid triage | Confirmatory / reflex testing |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor
DHA Registration ID: 61713011 | Specialist Diagnostic Radiology
"The TFE3 IHC assay serves as a powerful first-line triage tool for identifying Xp11.2 translocation-associated neoplasms, yet its interpretation demands full integration with histomorphology, clinical presentation, and cross-sectional imaging findings. A positive nuclear staining result in a renal tumor strongly suggests Xp11.2 translocation RCC, while in soft tissue lesions it points toward alveolar soft part sarcoma โ both entities requiring distinct oncological management pathways. A negative or equivocal IHC result does not completely exclude TFE3-rearranged neoplasms; reflex FISH testing should be considered in clinically suspicious cases. I strongly advise all patients to review these results directly with their treating oncologist or surgical pathologist before making any treatment decisions."
Critical Safety Advisory
Do not discontinue any prescribed cancer-directed therapy, targeted agent, or supportive medication based solely on pending or preliminary TFE3 IHC results. Altering your treatment regimen without direct oncologist consultation may lead to disease progression, treatment resistance, or preventable adverse events. This advisory is issued in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability regarding patient safety and informed consent.
Exclusion Criteria โ Do Not Proceed with Specimen Submission If:
- No prior histopathology report or biopsy documentation is available for the target lesion.
- The tissue block or slide has been compromised, improperly fixed, or stored in non-recommended media outside 10% neutral buffered formalin.
- The patient is under 18 years of age and lacks a legal guardian's documented consent (per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Insufficient tumor cellularity is noted on preliminary review (less than 50 viable tumor cells).
Emergency Red Flags โ Seek Immediate Medical Attention If:
- Acute onset of severe pain, uncontrolled bleeding, or sudden neurological deficit.
- Rapidly enlarging mass with overlying skin breakdown or fungation.
- Signs of spinal cord compression: bilateral leg weakness, saddle anesthesia, or incontinence.
- Febrile neutropenia (temperature above 38.3ยฐC with neutrophil count below 500 cells/ยตL) in patients undergoing concurrent chemotherapy.
Patient FAQ & Clinical Guidance
1. What does a positive TFE3 IHC result mean for my cancer diagnosis and treatment plan?
A positive TFE3 immunohistochemistry result indicates strong nuclear expression of the TFE3 protein within your tumor cells, which is highly suggestive of Xp11.2 translocation renal cell carcinoma if the specimen is from kidney tissue, or alveolar soft part sarcoma if the specimen originates from soft tissue, and this finding directly guides your oncologist's targeted therapy selection and clinical trial eligibility assessment. Your treating oncologist will integrate this result with radiological staging, molecular profiling, and your overall performance status to formulate a personalized treatment strategy โ which may include tyrosine kinase inhibitors, mTOR pathway agents, or immune checkpoint inhibitors depending on the final integrated diagnosis. Please schedule a dedicated consultation to discuss your individualized care pathway.
2. How should I prepare my tissue sample and what documents are absolutely required?
You must submit the formalin-fixed paraffin-embedded tissue block or freshly sectioned unstained slides from the original biopsy along with a complete copy of the corresponding histopathology report, the precise anatomical site of the biopsy, and a detailed clinical history summary as these are mandatory prerequisites for accurate immunohistochemical interpretation and DHA-compliant laboratory processing. If you are using our secure medical courier retrieval service, our team will coordinate directly with your referring hospital's pathology department to retrieve the block under cold-chain protocol โ simply provide the original biopsy report and hospital details at the time of booking. Block retrieval typically adds 24โ48 hours to the total turnaround time.
3. How long does it take to receive results and what are the next steps after the report is issued?
TFE3 immunohistochemistry results are typically available within five to seven business days depending on specimen size and tissue complexity. The final report is delivered directly to your treating physician, and a telephonic consultation with our pathology specialist can be arranged to discuss the findings in detail. Once the report is received, your oncologist will review the integrated diagnosis and determine the appropriate treatment plan, which may include surgery, targeted therapy, or immunotherapy. We recommend scheduling a follow-up consultation promptly after results are issued to ensure timely therapeutic intervention.
4. What are the advantages of choosing TFE3 IHC over FISH testing for initial evaluation?
TFE3 IHC offers several advantages as a first-line screening tool: faster turnaround time (5โ7 days versus 10โ14 days for FISH), significantly lower cost (450 AED compared to 1,200โ2,500 AED for FISH), and the ability to directly visualize protein expression in the context of tissue morphology. IHC is performed on the same FFPE block used for routine histology, requiring no additional tissue processing. While FISH remains the gold standard for confirming TFE3 gene rearrangement, IHC provides a highly sensitive and cost-effective screening method that can guide the need for reflex FISH testing, thereby optimizing resource utilization and reducing time to clinical decision-making.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 45 of 2021 (PDPL)
All patient genomic, proteomic, and histopathological data is fully encrypted, stored on UAE-sovereign servers, and processed exclusively within the national territory in full compliance with the UAE Personal Data Protection Law (PDPL). Strict access controls and audit trails are maintained for all data handling operations.
Federal Law No. 2 of 2019 โ Health ICT
Full adherence to the provisions of Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure electronic health data exchange, interoperable health information systems, and protection of patient health records across all digital platforms.
Federal Decree-Law No. 4 of 2016 โ Medical Liability
All clinical testing procedures, patient consent protocols, and safety standards are strictly aligned with Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring comprehensive patient protection, informed consent documentation, and professional accountability across the diagnostic pathway.
Clinical & Logistical Metadata
| Test Name | TFE3 Immunohistochemistry (IHC) Test |
| Price (AED) | 450 AED |
| Turnaround Time | 5โ7 Business Days (Block: 5 Days, Biopsy: 5 Days, Large Complex Tissue: 7 Days) |
| Sample Type / Matrix | FFPE Tissue Block / Biopsy Slides / Tumor Tissue in 10% Neutral Buffered Formalin โ Archival Tissue Specimen. Secure Medical Courier Solid Tissue Specimen Retrieval from referring hospital pathology department. |
| Methodology Used | Immunohistochemistry (IHC) with polymer-based detection and heat-induced epitope retrieval |
| ICD-10-CM Code | C64.9, C49.9, Z85.528 |
| LOINC Code | 72381-7 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians